UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40478 LifeStance Health Group, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 86-1832801 | | --- | --- ...

LifeStance Health Group (LFST) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this outpatient mental health services provider would post a loss of $0.09 per share when it actually produced a loss of $0.12, delivering a surprise of -33.33%.Over the ...

(All results compared to prior-year comparative period, unless otherwise noted) Q1 2024 Highlights and FY 2024 Outlook "I'm proud of the results achieved by our clinicians and team members this quarter. We met or exceeded expectations for the sixth consecutive quarter while delivering organic revenue growth of 19% and driving margin expansion," said Ken Burdick, Chairman and CEO of LifeStance. "We also successfully navigated cash collection challenges that affected many healthcare providers, reinforcing Lif ...

SCOTTSDALE, Ariz., April 18, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its first quarter 2024 earnings release before the market opens on Thursday, May 9, 2024. LifeStance will host a live earnings conference call to discuss first quarter results on May 9, 2024, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and u ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40478 LifeStance Health Group, Inc. (Exact name of Registrant as specified in its Charter) Delaware 86-1832801 (State or other jurisd ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Monica Prokocki - Vice President, Investor Relations Ken Burdick - Chief Executive Officer David Bourdon - Chief Financial Officer Danish Qureshi - President and Chief Operating Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JP Morgan Jack Senft - William Blair Dylan Finley - UBS Brian Tanquilut - Jefferies Stephanie Davis - Barclays Operator Good ...

Financial Performance - Fourth quarter revenue increased by 22% to $280.6 million, and full year revenue rose by 23% to $1,055.7 million compared to $859.5 million[5]. - Total revenue for 2023 was $1,055,665, an increase of 22.8% from $859,542 in 2022[22]. - The net loss for Q4 was $45.0 million, a 4% decrease from the previous year, and the full year net loss was $186.3 million, a 14% decrease[5]. - Net loss for 2023 was $186,262, compared to a net loss of $215,564 in 2022, showing an improvement of 13.6%[22]. - Net loss for the year ended December 31, 2023, was $186,262 thousand, an improvement from a net loss of $215,564 thousand in 2022, and $307,197 thousand in 2021[28]. - Adjusted EBITDA for Q4 was $20.3 million, a 99% increase, and for the full year, it was $59.0 million, a 12% increase[5]. - Adjusted EBITDA for 2023 was $59,042 thousand, compared to $52,670 thousand in 2022 and $49,154 thousand in 2021, indicating a year-over-year increase of 12.9%[28]. Operational Metrics - The clinician base grew by 18% to 6,645 clinicians, with 227 net clinician additions in Q4 and 1,014 for the full year[5]. - Fourth quarter visit volumes increased by 20% to 1.8 million, and full year visit volumes also rose by 20% to 6.9 million[5]. - The Center Margin for Q4 grew by 33% to $83.3 million, representing 29.7% of total revenue, while for the full year, it increased by 27% to $302.1 million, or 28.6% of total revenue[6]. - Center margin for 2023 was $302,096, up from $237,017 in 2022, representing a 27.5% increase[26]. Cash Flow and Debt - The company ended Q4 with cash of $78.8 million and net long-term debt of $280.3 million[8]. - Cash and cash equivalents decreased to $78,824 at the end of 2023 from $108,621 at the end of 2022, a decline of 27.5%[24]. - Cash used in operating activities was $(16,884) in 2023, a significant decrease from $52,789 in 2022[24]. - Net cash used in investing activities was $(60,340) in 2023, down from $(139,461) in 2022, indicating a 56.7% improvement[24]. - Net cash provided by financing activities was $47,427 in 2023, slightly up from $47,264 in 2022[24]. Expenses and Costs - Operating expenses totaled $1,244,799 in 2023, up from $1,069,716 in 2022, reflecting a 16.3% increase[22]. - Litigation costs for 2023 amounted to $51,034 thousand, primarily related to three distinct litigation matters, reflecting significant non-recurring expenses[30]. - Strategic initiatives expenses in 2023 included costs for a multi-phase system upgrade, focusing on human resources management, clinician credentialing, and a scalable electronic health resources system[31]. - Real estate optimization and restructuring charges in 2023 totaled $10,970 thousand, associated with a strategic project to consolidate physical locations[32]. - Stock and unit-based compensation expense decreased to $99,388 thousand in 2023 from $187,430 thousand in 2022, showing a reduction of 46.9%[28]. - Interest expense, net for 2023 was $21,220 thousand, slightly increasing from $19,928 thousand in 2022[28]. - Depreciation and amortization expenses rose to $80,437 thousand in 2023 from $69,198 thousand in 2022, indicating increased investment in assets[28]. Future Outlook - The company expects full year 2024 revenue to be between $1.19 billion and $1.24 billion, with a Center Margin of $345 to $365 million and Adjusted EBITDA of $80 to $90 million[13]. - For Q1 2024, the company anticipates total revenue of $287 to $307 million, with a Center Margin of $81 to $93 million and Adjusted EBITDA of $17 to $23 million[13].

LifeStance Health Group, Inc. (NASDAQ:LFST) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Monica Prokocki - Vice President, Investor Relations Ken Burdick - Chief Executive Officer Dave Bourdon - Chief Financial Officer Danish Qureshi - Chief Operating Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JP Morgan Jack Senft - William Blair Kevin Caliendo - UBS Jamie Perse - Goldman Sach Brian Tanquilut - Jefferies Gary Taylor - TD Cowen Oper ...

Use of Non-GAAP Financial Measures Market and Industry Data Forward-Looking Statements In addition to financial measures presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation includes certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, Adjusted EBITDA Margin and Free Cash Flow. These non-GAAP measures are in addition to, and not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40478 LifeStance Health Group, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 86-1832801 | | --- | ...